Prolactin Hormone in Oral Lichen Planus

Prolactin Hormone in Oral Lichen Planus Tissue Samples

Oral lichen planus (OLP) is one of the most common mucosal diseases with autoimmune etio-pathogenesis with involvement of various cytokines similar to psoriasis.It generally occurs more commonly in females, in a ratio of 3:2. prolactin (PRL),It is a peptide hormone that has a role in autoimmune related diseases like systemic lupus erythematosus and , rheumatoid Artheritis. The role of PrL in OLP pathogenesis was never investigated.the aim of this study is to investigate the expression of PRL receptors in tissue biopsies of OLP patients.

Study Overview

• Status: Completed
• Conditions: Oral Lichen Planus

• Study Type: Observational
• Enrollment (Actual): 40

Contacts and Locations

Study Locations

• Egypt
  • Giza, Egypt
    • October University for Modern Sciences and Arts

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 58 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Egyptian patients with OLP

Description

Inclusion Criteria:

• patients with oral lichen planus
• systemically healthy

Exclusion Criteria:

• oral lichenoid lesions

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
oral lichen planus group; patients with chronic bollus erosive lichen planus

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
prolactin receptors expression in oral mucous membrane	immuno-histochemistry	24 hours

Collaborators and Investigators

• Sponsor: October University for Modern Sciences and Arts
• Collaborators: Al-Azhar University

Study record dates

Study Major Dates

• Study Start (Actual): June 19, 2020
• Primary Completion (Actual): August 22, 2020
• Study Completion (Actual): December 10, 2020

Study Registration Dates

• First Submitted: March 3, 2021
• First Submitted That Met QC Criteria: March 3, 2021
• First Posted (Actual): March 8, 2021

Study Record Updates

• Last Update Posted (Actual): March 8, 2021
• Last Update Submitted That Met QC Criteria: March 3, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Stomatognathic Diseases; Mouth Diseases; Skin Diseases, Papulosquamous; Lichenoid Eruptions; Lichen Planus, Oral; Lichen Planus
• Other Study ID Numbers: REC18-048

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No